NCT02624349View on ClinicalTrials.gov

Immunogenicity and Safety of Human Papilloma Virus Vaccine in Solid Organ Transplant Recipients

PHASE4CompletedINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

October 31, 2013

Primary Completion Date

December 31, 2017

Study Completion Date

December 31, 2017

Conditions
Late Complication From Kidney TransplantComplication of Transplanted LiverHuman Papillomavirus-Related Carcinoma
Interventions
DRUG

Quadravalent human papillomavirus vaccine

Vaccine will be administered to all transplant recipients. Controls will be recruited based on previous documented receipt of vaccine

Trial Locations (1)

M5G1X8

The Hospital for Sick Children, Toronto

All Listed Sponsors
collaborator

The Physicians' Services Incorporated Foundation

OTHER

collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

The Hospital for Sick Children

OTHER

NCT02624349 - Immunogenicity and Safety of Human Papilloma Virus Vaccine in Solid Organ Transplant Recipients | Biotech Hunter | Biotech Hunter